| Literature DB >> 34201912 |
Nasir Tajuddeen1, Tarryn Swart2, Heinrich C Hoppe2, Fanie R van Heerden1.
Abstract
Ethnobotanical surveys indicate that the Masai and Kikuyu in Kenya, the Venda in South Africa, and the Gumuz people of Ethiopia use Pappea capensis for the treatment of malaria. The present study aimed to investigate the phytochemical and antiplasmodial properties of the plant leaves. The bioactive compounds were isolated using chromatographic techniques. The structures were established using NMR, HRMS, and UV spectroscopy. Antiplasmodial activity of P. capensis leaf extract and isolated compounds against chloroquine-sensitive 3D7 P. falciparum was evaluated using the parasite lactate dehydrogenase assay. Cytotoxicity against HeLa (human cervix adenocarcinoma) cells was determined using the resazurin assay. The extract inhibited the viability of Plasmodium falciparum by more than 80% at 50 µg/mL, but it was also cytotoxic against HeLa cells at the same concentration. Chromatographic purification of the extract led to the isolation of four flavonoid glycosides and epicatechin. The compounds displayed a similar activity pattern with the extract against P. falciparum and HeLa cells. The results from this study suggest that the widespread use of P. capensis in traditional medicine for the treatment of malaria might have some merits. However, more selectivity studies are needed to determine whether the leaf extract is cytotoxic against noncancerous cells.Entities:
Keywords: HeLa cells; Pappea capensis; Sapindaceae; antiplasmodial; flavonoids; malaria
Mesh:
Substances:
Year: 2021 PMID: 34201912 PMCID: PMC8270286 DOI: 10.3390/molecules26133875
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of the isolated compounds from P. capensis.
In vitro antiplasmodial and cytotoxic activity of the extract and isolated compounds. Viability of P. falciparum was assessed after 48 h of incubation with the extract/compound, while HeLa cells’ viability was determined after 24 h incubation.
| Compound | Viability% ± SD (50 µg/mL) | Viability% ± SD (10 µg/mL) | ||
|---|---|---|---|---|
| 3D7 | HeLa | 3D7 | HeLa | |
|
| 12.1 ± 0.2 | 1.9 ± 0.2 | 93.1 ± 3.8 | 71.4 ± 6.1 |
|
| 19.1 ± 0.5 | 2.8 ± 0.1 | 68.4 ± 3.4 | 72.4 ± 5.4 |
|
| 16.2 ± 2.2 | 1.4 ± 0.1 | 66.8 ± 2.6 | 71.3 ± 4.5 |
|
| 18.1 ± 1.0 | 3.1 ± 0.1 | 83.1 ± 3.5 | 70.9 ± 3.7 |
|
| 18.4 ± 2.9 | 1.9 ± 0.6 | 58.7 ± 1.9 | 64.8 ± 2.2 |
| Chloroquine a | - | - | <10 ± 2.1 | - |
| Emetine b | - | - | - | <5 ± 1.3 |
a IC50 against Plasmodium falciparum 3D7 strain 0.0045 µg/mL (0.014 μM), b IC50 against HeLa cells IC50 = 0.192 µg/mL (0.04 µM).